Curasight A/S (NGM:CURAS)

Market Cap	292.45M
Revenue (ttm)	n/a
Net Income (ttm)	-63.65M
Shares Out	45.87M
EPS (ttm)	-1.88
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,410
Average Volume	46,324
Open	4.200
Previous Close	4.420
Day's Range	3.930 - 4.640
52-Week Range	1.800 - 13.400
Beta	0.02
RSI	39.45
Earnings Date	Nov 27, 2025

About Curasight

Curasight A/S develops therapeutic and diagnostic solutions for the treatment of cancer. It develops uTREAT therapeutic solutions, that are in Phase IIb clinical trials to treat glioblastoma, non-small cell lung cancers, neuroendocrine neoplasms, head and neck cancer, and pancreatic cancers. The company is also developing uTRACE diagnostic solutions, which have completed Phase II clinical trial for the treatment of glioblastoma, prostate cancer, neuroendocrine neoplasms, head and neck cancer, breast cancer, and urinary bladder cancer; and is in...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2013
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: CURAS

Financial Performance

Financial numbers in DKK